Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 14, 2025. The filing serves to announce the Company's results of operations for the fiscal quarter ended June 30, 2025. The Company's common stock trades on The Nasdaq Capital Market under the symbol "COCP."
Financial Metrics
This Form 8-K is a notification of the release of financial results and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. The filing states that the detailed results are contained in a press release furnished as Exhibit 99.1, which is not included in the provided text. Therefore, the filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It only confirms that results for the quarter ended June 30, 2025, have been issued.
Guidance, Outlook, and Risks
The filing does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the specific financial results (revenue, net loss, cash position) by reviewing the press release dated August 14, 2025, referenced as Exhibit 99.1.
- Confirm the Company's cash runway and burn rate, as these are critical for a clinical-stage biopharmaceutical company but are not listed in this summary filing.
- Review the full text of the press release for any updates on clinical trial progress or regulatory milestones for the Company's drug candidates.
- Note that the filing was signed by James Martin, Chief Financial Officer and Co-Chief Executive Officer.